Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - 70a~* Subjects understand study related activities and give written informed concent~* HbA1c between 7 - 10 % under treatment with premixed insulin (2-3 injections)~Exclusion Criteria:~* Females of child-bearing age~* History of hypoglycemia unawareness~* Gastrointestinal disease associated with prolonged nausea and vomiting~* Impaired liver function (transaminase \>2x than normal)~* Impaired kidney function (creatinin \> 1,2 mg/dl)~* Known intolerance against GLP-1 receptor agonists~* History of pancreatitis or pancreas tumor~* Malignancies, autoimmune diseases~* Severe dyslipidemia (serum triglycerides \> 400 mg/dl, cholesterol \> 300 mg/dl)~* Psychiatric disorder~* Oral glucose lowering medication except for metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Intervention group (Type: EXPERIMENTAL): 10 type 2 diabetic patients will be included to perform in this study and will be switched from premixed insulin to insulin glargine and lixisenatide

Based on this trial design, predict the completion outcome and termination type (if applicable).